BioNTech has argued that his COVID-19 vaccinedeveloped by the pharmaceutical Pfizerit is “original”behind the demand for modern in which he accuses them of copying the patent for mRNA technology, on which the vaccines are based.
From the German company they assure that his work is “original” and that in this way they defend themselves against “all patent infringement accusations”. In this sense, he also argues that value and respect all intellectual property rights valid and enforceable rights of others and continue to trust your intellectual property.
The lawsuit filed by Moderna It is “unfortunate, but quite common” within the pharmaceutical and scientific world. “It is normal for other companies to claim that a successful product potentially infringes their intellectual property rights, even more so in this case after witnessing the historic achievements of a vaccine like ours,” they point out.
Modern demand
In the lawsuit, filed in the United States District Court for the District of Massachusetts and the Düsseldorf Regional Court in Germany, Moderna alleges that the Pfizer and BioNTech “infringes” the patents that Moderna filed between 2010 and 2016 about his mRNA technologysince they consider that this “innovative” technology was essential for the development of the COVID-19 vaccine itself.”
Modern believes that Pfizer and BioNTech copied two key features of the technologies patented by them that were the ones that led to the success of mRNA vaccines. From the company they explain that neither Pfizer nor BioNTech had Moderna’s level of expertise in developing mRNA vaccines for infectious diseases, and knowingly went the way of Moderna to develop their own vaccine.
Two other aspects are also highlighted in the lawsuit. First, Moderna argued that Pfizer and BioNTech “brought four different vaccine candidates to clinical trials, which included options that would have strayed from Moderna’s innovative path.” “However, Pfizer and BioNTech ultimately decided proceed with a vaccine that has the same chemical modification of the mRNA as Moderna’sstudied in 2010 and validated in human trials in 2015.
Second, Moderna charged that “despite having many different options,” Pfizer and BioNTech “copied Moderna’s approach to encode the full-length spike protein in a lipid nanoparticle formulation for a coronavirus.” Scientists at Moderna developed this approach when they created a vaccine for the coronavirus that causes Middle East Respiratory Syndrome (MERS) years before the emergence of COVID-19.
